Calcium channel blockers and beta blockers in pediatric supraventricular tachycardia.
beta blocker
calcium channel blocker
supraventricular tachycardia
Journal
Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756
Informations de publication
Date de publication:
23 Sep 2024
23 Sep 2024
Historique:
revised:
02
08
2024
received:
06
06
2024
accepted:
05
09
2024
medline:
24
9
2024
pubmed:
24
9
2024
entrez:
24
9
2024
Statut:
aheadofprint
Résumé
Supraventricular tachycardia (SVT) is a common pediatric arrhythmia. Beta blockers (BBs) and calcium channel blockers (CCBs) are used for treatment despite little data examining their use. We describe the prescriptive tendencies, efficacy, and tolerability of BBs and CCBs used in the treatment of pediatric SVT. This is a multicenter retrospective cohort study from three academic children's hospitals. Individuals aged 1-21 years at time of SVT diagnosis initiated on a BB or a CCB between 01/01/2010 and 12/31/2020 were included. Exclusion criteria were pre-excitation, ectopic atrial tachycardia, and hemodynamically significant heart disease. Demographic, comorbidity, symptomatology, and medication data were collected. Treatment success was defined using a composite data abstraction tool. Of 164 patients, 151 received a BB and 13 received a CCB. The success rate on the initial dosage was 46% for both BB and CCB; the success rate following dosage adjustments was also comparable for BBs (98/151, 65%) and CCBs (9/13, 69%). While 27 (18%) BB patients experienced intolerable side effects, no CCB patient did. Treatment with a BB or CCB was successful in half of patients. BBs were prescribed more frequently than CCBs but were associated with more side effects.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Kotadia ID, Williams SE, O'Neill M. Supraventricular tachycardia: an overview of diagnosis and management. Clin Med. 2020;20(1):43‐47.
Weindling SN, Saul JP, Walsh EP. Efficacy and risks of medical therapy for supraventricular tachycardia in neonates and infants. Am Heart J. 1996;131(1):66‐72.
Aljohani OA, Herrick NL, Borquez AA, et al. Antiarrhythmic treatment duration and tachycardia recurrence in infants with supraventricular tachycardia. Pediatr Cardiol. 2021;42(3):716‐720.
Sanatani S, Potts JE, Reed JH, et al. The study of antiarrhythmic medications in infancy (SAMIS): a multicenter, randomized controlled trial comparing the efficacy and safety of digoxin versus propranolol for prophylaxis of supraventricular tachycardia in infants. Circ: Arrhythmia Electrophysiol. 2012;5(5):984‐991.
Hill AC, Silka MJ, Bar‐Cohen Y. A comparison of oral flecainide and amiodarone for the treatment of recurrent supraventricular tachycardia in children. Pacing Clin Electrophysiol. 2019;42(6):670‐677.
DeWitt CR, Waksman JC. Pharmacology, pathophysiology and management of calcium channel blocker and beta‐blocker toxicity. Toxicol Rev. 2004;23(4):223‐238.
Huffman JC, Stern TA. Neuropsychiatric consequences of cardiovascular medications. Dialogues Clin Neurosci. 2007;9(1):29‐45.
Tiotiu A, Novakova P, Kowal K, et al. Beta‐blockers in asthma: myth and reality. Expert Rev Respir Med. 2019;13(9):815‐822.